Enzymes that Unlock
Your Next Discovery
0
0
Resources
Company
Contact
X

Essential insights based on 3rd party publications:

Get the White Paper now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

Quantification Challenges of Chromatin — Associated Host Cell DNA:
An Underestimated Risk

  • Discover why host cell DNA quantities are often significantly underestimated.
  • Understand the limitation of conventional nucleases when degrading chromatin

Download the poster here
and get access to the
interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

The Largest Overlooked Cost Driver in Viral Vector Production

  • Up to half of produced vector is lost during Down Stream Processing(DSP)
  • The majority of manufacturing cost accumulates is DSP raw materials
  • Nuclease design decisions determine downstream economics

Download here and get access to the interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Investors News

ArcticZymes ASA Appoints New Exclusive European Distributor for its Bioprocess Nuclease Range

Oct 29, 2025

ArcticZymes is pleased to announce a new, exclusive European distributor agreement with Brenntag Specialists Pharma to compliment its existing commercial team, supply the SAN-HQ and M-SAN HQ product lines.

Read More
Read More

ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum

Aug 14, 2025

Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company’s commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and reinforces ArcticZymes’ role as a reliable partner in gene therapy workflows.

Read More
Read More

ArcticZymes Technologies Launches GMP-Grade Nuclease for Next-Generation Viral Vector Manufacturing.

Jun 16, 2025

We are pleased to announce the expansion of our GMP product range, with the introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for viral vector manufacturing.

Read More
Read More

ArcticZymes Technologies ASA Q4 2024 Results & Presentation

Feb 13, 2025

Tromsø, Norway, February 13th, 2025 – ArcticZymes Technologies (OSE: AZT) reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.

Read More
Read More